Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
Rhea-AI Summary
Ocugen (NASDAQ: OCGN) announced that Dr. Shankar Musunuri, chairman, CEO, and co-founder, will present at the Oppenheimer Movers in Rare Disease Summit at the Sofitel New York on Thursday, December 11, 2025. The presentation is a fireside chat titled "Fireside Chat with Aldeyra and Ocugen: Setting Sights on Inherited Retinal Dystrophies" scheduled for 9:45–10:05 a.m. ET in the Second Floor Ballroom, Track 1.
Ocugen said its executive team will also hold one-on-one investor meetings to review the company’s gene-modifier therapy platform, clinical development strategy, and expected catalysts in 2026.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: FDMT -4.45%, MBX -7.96%, DSGN -5.5% versus BNTC +0.91% and LRMR +8.04%, suggesting stock-specific rather than broad sector action around this CEO summit appearance.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 20 | Conference presentation | Neutral | -2.6% | CEO presentation at NobleCon21 and investor meetings on strategy. |
| Nov 05 | Earnings update | Positive | -1.4% | Q3 2025 results, financing and clinical progress for OCU400/OCU410ST. |
| Oct 23 | Earnings call setup | Neutral | +1.3% | Scheduled webcast to discuss Q3 2025 results and business update. |
| Oct 02 | Conference schedule | Positive | +5.4% | Participation in three major October conferences and BLA timeline goals. |
| Sep 15 | Licensing deal | Positive | +12.2% | Exclusive Korean OCU400 license with milestones and 25% royalties. |
Recent conference and business updates often saw positive or modest price gains, while one earnings/business update and one presentation event drew mild negative reactions, showing mixed but generally constructive responses to visibility and partnership news.
Over the past six months, Ocugen highlighted strategic progress across conferences, financing, and partnerships. In September 2025, a Korean OCU400 license with potential milestones drove a 12.15% gain. October conference participation and BLA goals coincided with a 5.36% rise. Earnings and business updates in November 2025 produced modest declines despite financing and clinical milestones. The latest November conference presentation saw a small pullback. Today’s Oppenheimer rare disease summit appearance continues this pattern of investor-focused visibility and discussion of the modifier gene therapy platform and upcoming catalysts.
Market Pulse Summary
This announcement highlights Ocugen’s continued visibility push, with its CEO presenting at the Oppenheimer Movers in Rare Disease Summit and holding investor meetings. It reinforces focus on a novel modifier gene therapy platform and a gene-agnostic approach for rare and age-related blindness diseases. In recent months, the company combined licensing deals, conference exposure, and financing activity with ambitions for multiple BLAs. Investors may watch upcoming 2026 catalysts, funding developments, and progress in inherited retinal dystrophies.
Key Terms
gene therapies medical
modifier gene therapy medical
AI-generated analysis. Not financial advice.
MALVERN, Pa., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-founder, will present at the Oppenheimer Movers in Rare Disease Summit taking place at the Sofitel New York on Thursday, December 11, 2025.
“For the second year in a row, we will join leaders advancing groundbreaking discoveries for rare disease at this significant meeting,” said Dr. Musunuri. “I look forward to sharing more about Ocugen’s novel modifier gene therapy platform with a gene-agnostic approach that has the potential to treat the entire disease and in turn large patient populations—in both rare and age-related blindness diseases.”
Details regarding the fireside chat are as follows:
Title: Fireside Chat with Aldeyra and Ocugen: Setting Sights on Inherited Retinal Dystrophies
Date: Thursday, December 11, 2025
Location: Second Floor Ballroom, Track 1
Time: 9:45-10:05 a.m. ET
In addition to Dr. Musunuri’s session, members of Ocugen’s executive team will conduct one-on-one meetings with investors to highlight the Company’s business and clinical development strategy and upcoming catalysts in 2026.
About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on X and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Contact:
Tiffany Hamilton
AVP, Head of Communications
Tiffany.Hamilton@ocugen.com
FAQ
When will Ocugen (OCGN) present at the Oppenheimer Movers in Rare Disease Summit?
What is the title of Ocugen's (OCGN) presentation at the December 11, 2025 summit?
Who from Ocugen (OCGN) will speak at the Oppenheimer Rare Disease Summit?
Where is Ocugen's (OCGN) fireside chat being held on December 11, 2025?
Will Ocugen (OCGN) meet with investors at the summit and what will they discuss?
What therapeutic focus will Ocugen (OCGN) highlight at the Oppenheimer summit?
